首页> Headache> A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients.

A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients.

导出原文传递

翻译打印收藏纠错

第一作者： Dikla,Gutman

第一单位： Research and Development, Teva Pharmaceutical Industries, Netanya, Israel.

作者： Dikla,Gutman ^[1] ; Edward,Hellriegel ^[2] ; Ernesto,Aycardi ^[3] ; Marcelo E,Bigal ^[3] ; Jeevan,Kunta ^[2] ; Rohini,Chitra ^[3] ; Sujay,Kansagra ^[4] ; Orna Srur,Kidron ^[1] ; Helena,Knebel ^[5] ; Steven,Linder ^[6] ; Yuju,Ma ^[3] ; Mark,Pierce ^[7] ; Paul K,Winner ^[8] ; Ofer,Spiegelstein ^[9]

作者单位： Research and Development, Teva Pharmaceutical Industries, Netanya, Israel. ^[1] Research and Development, Teva Pharmaceutical Industries, West Chester, PA, USA. ^[2] Clinical Development, Teva Pharmaceutical Industries, Frazer, PA, USA. ^[3] Children's Health Center, Duke University Medical Center, Durham, NC, USA. ^[4] Patient Safety & Pharmacovigilance, Teva Pharmaceutical Industries, Petach Tikva, Israel. ^[5] Dallas Pediatric Neurology Associates, Dallas, TX, USA. ^[6] NuPathe Inc, Conshohocken, PA, USA. ^[7] Palm Beach Neurology - Premiere Research Institute, West Palm Beach, FL, USA. ^[8] Research and Development, Teva Pharmaceutical Industries, Netanya, Israel. Ofer.Spiegelstein@teva.co.il. ^[9]

关键词 Zecuity adolescents iontophoretic transdermal system migraine pharmacokinetics sumatriptan